Free Trial
NASDAQ:CGEM

Cullinan Therapeutics Q1 2026 Earnings Results & Report

Cullinan Therapeutics logo
$10.28 +0.09 (+0.88%)
Closing price 11/13/2026 04:00 PM Eastern
Extended Trading
$10.27 -0.01 (-0.10%)
As of 11/13/2026 07:30 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Cullinan Therapeutics beat analyst earnings expectations in its Q1 2026 results, released May 7, 2026. The company reported EPS of -$0.75 versus the -$0.8359 consensus estimate.

Earnings Announcement Details

Quarter
Q1 2026
Report Date
Time
Before Market Opens
Conference Call
7:00 AM ET

Cullinan Therapeutics EPS Results

Actual EPS
-$0.75
Consensus EPS
-$0.8359
Beat/Miss
Beat by +$0.0859
One Year Ago EPS
N/A
EPS Beat Rate
6 of last 8 quarters

Cullinan Therapeutics Revenue Results

Actual Revenue
N/A
Expected Revenue
$3.67 million
Beat/Miss
N/A
YoY Revenue Growth
N/A

Cullinan Therapeutics Q1 2026 Earnings FAQ

Cullinan Therapeutics (NASDAQ:CGEM) reported earnings of -$0.75 per share for Q1 2026, beating the consensus estimate of -$0.8359. The report was announced on Thursday, May 7, 2026.

Cullinan Therapeutics Earnings Headlines

Cullinan Therapeutics (NASDAQ:CGEM) Price Target Raised to $44.00
BTIG Reaffirms Their Buy Rating on Cullinan Management (CGEM)
Your free book is about to disappear
Bill Poulos is giving away his 'Safe Trade Options Formula' book for free - but only for a limited time through a temporary download link. He plans to charge for it soon. Download your copy now and lock it in at no cost, regardless of future pricing.tc pixel
See More Cullinan Therapeutics Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Cullinan Therapeutics? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Cullinan Therapeutics and other key companies, straight to your email.

About Cullinan Therapeutics

Cullinan Therapeutics (NASDAQ:CGEM) is a clinical-stage biopharmaceutical company developing treatments for cancer and autoimmune diseases. The company advances a pipeline of investigational medicines, including antibody-based therapies and T-cell engagers designed to direct immune responses against disease-related cells.

Its programs include CLN-619, an antibody being studied for solid tumors; CLN-049, a T-cell engager targeting FLT3 for acute myeloid leukemia; and CLN-978, a CD19-targeting T-cell engager being developed for B-cell-mediated autoimmune diseases. These candidates remain investigational and are not approved treatments.

Founded as Cullinan Oncology, the company adopted the name Cullinan Therapeutics in 2024 to reflect its expanded focus beyond oncology. It is headquartered in Cambridge, Massachusetts, and is led by President and Chief Executive Officer Nadim Ahmed.

View Cullinan Therapeutics Profile